𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Continuing scientific concerns about the validity of the l-tryptophan eosinophilia-myalgia syndrome association

✍ Scribed by Stephen R. Daniels; James I. Hudson; Ralph I. Horwitz

Book ID
116154987
Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
410 KB
Volume
48
Category
Article
ISSN
0895-4356

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The eosinophilia-myalgia syndrome associ
The eosinophilia-myalgia syndrome associated with ingestion of l-tryptophan
✍ Lawrence E. Shulman 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB 👁 2 views

physicians in New Mexico notified the New Mexico Department of Health and Environment of 3 patients with marked eosinophilia and severe. incapacitating myalgia who had been taking the amino acid L-tryptophan (orally) and whose illness, after thorough clinical evaluation, seemed both unusual and obsc

L-tryptophan—associated eosinophilic fas
L-tryptophan—associated eosinophilic fasciitis prior to the 1989 eosinophilia—Myalgia syndrome outbreak
✍ Jonathan R. Hibbs; Barbara Mittleman; Paula Hill; Thomas A. Medsger Jr. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 1 views

Objective. To investigate the relationship between L-tryptophan (LT) ingestion and eosinophilic fasciitis (EF) occurring prior to the outbreak of eosinophiliamyalgia syndrome in 1989. ## Methods. Interviews and record reviews of 45 EF case-patients and 126 polymyositis patients (controls) diagnosed

Absent neutrophil alkaline phosphatase i
Absent neutrophil alkaline phosphatase in the eosinophilia myalgia syndrome associated with L-tryptophan use
✍ Dr. Jeffrry P. Jaffe; Elie Gertner; Wesley Miller 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

The clinical constellation of leukocytosis, thrombocytosis, and low or absent stainable neutrophil alkaline phosphatase (NAP) is considered characteristic of chronic myelogenous leukemia (CML) [l]. CML with eosinophilic differentiation (eosinophilic leukemia) is well described [2], and leukemia and

Immunogenetic risk and protective factor
Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms
✍ Okada, Satoshi ;Kamb, Mary L. ;Pandey, Janardan P. ;Philen, Rossanne M. ;Love, L 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

## Abstract ## Objective To assess L‐tryptophan (LT) dose, age, sex, and immunogenetic markers as possible risk or protective factors for the development of LT‐associated eosinophilia–myalgia syndrome (EMS) and related clinical findings. ## Methods HLA–DRB1 and DQA1 allele typing and Gm/Km pheno